Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.43 |
| ▸ | PCNA | P12004 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488494 | 1.00 | ATM (0.49) | ATMITGB3ITGA2BITGB1ITGA4 | |
| SCHEMBL2291516 | 0.86 | ATM (0.59) | ATMITGB3ITGA2BPCNAHDAC8 | |
| SCHEMBL6479907 | 0.85 | KMT2A (0.50) | ATMITGB3ITGA2BHDAC8PTPN1 | |
| SCHEMBL6479900 | 0.85 | KMT2A (0.50) | ATMITGB3ITGA2BHDAC8PTPN1 | |
| SCHEMBL6478359 | 0.84 | PDE10A (0.49) | ATM | |
| SCHEMBL6478354 | 0.84 | PDE10A (0.49) | ATM | |
| SCHEMBL6478967 | 0.84 | RAB9A (0.49) | — | |
| SCHEMBL6478973 | 0.84 | RAB9A (0.49) | — | |
| SCHEMBL6479205 | 0.84 | TDP1 (0.53) | ATM | |
| SCHEMBL6479483 | 0.84 | ATM (0.45) | ATMITGB3ITGA2BPCNAHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | ATM 3918/4885ITGB3 262/4885ITGA2B 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.